
    
      This is a randomized, double-blind, placebo-controlled, parallel, 24-week, Phase 2
      safety/efficacy study in which three dose levels of EVP-6124 or placebo will be evaluated.
      Eligible for enrollment will be patients who meet clinical criteria for mild to moderate
      probable Alzheimer's disease who are either receiving treatment with AChEI medication at a
      stable dose or who are not presently taking any AChEI or memantine co-medication.

      Patients will be randomized to one of the following groups: 0.3 mg, 1 mg or 2 mg or Placebo.
      Approximately 400 subjects will be randomized to the 4 treatment groups. Study drug will be
      supplied as capsules and will be orally administered once daily for a total of 24 weeks.
    
  